dc.contributor
Institut Català de la Salut
dc.contributor
[Kayser S] Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany. Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. [Rahmé R] Hôpital Saint Louis, Université Paris Diderot, Paris, France. [Martínez-Cuadrón D] Hematology Department, Hospital Universitari i Politècnic, La Fe, Avinguda Fernando Abril Martorell, 106, 46026 València, Spain. CIBERONC, Instituto Carlos III, Madrid, Spain. [Ghiaur G] Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. [Thomas X] Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, Lyon, France. [Sobas M] Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland. [Salamero O] Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Kayser, Sabine
dc.contributor.author
Rahmé, Ramy
dc.contributor.author
Martínez-Cuadrón, David
dc.contributor.author
Ghiaur, Gabriel
dc.contributor.author
Thomas, Xavier
dc.contributor.author
Salamero García, Olga
dc.contributor.author
Sobas, Marta
dc.date.accessioned
2025-10-24T10:40:59Z
dc.date.available
2025-10-24T10:40:59Z
dc.date.issued
2021-11-19T13:21:09Z
dc.date.issued
2021-11-19T13:21:09Z
dc.identifier
Kayser S, Rahmé R, Martínez-Cuadrón D, Ghiaur G, Thomas X, Sobas M, et al. Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study. Leukemia. 2020 Sep;34(9):2333–41.
dc.identifier
https://hdl.handle.net/11351/6572
dc.identifier
10.1038/s41375-020-0758-4
dc.identifier
000514536700002
dc.identifier.uri
https://hdl.handle.net/11351/6572
dc.description.abstract
Leucèmia mieloide aguda; Genètica clínica
dc.description.abstract
Leucemia mieloide aguda; Genética clínica
dc.description.abstract
Acute myeloid leukaemia; Clinical genetics
dc.description.abstract
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during consolidation (CTX/ATRA/ATO; n = 148), or with CTX/ATRA (n = 259). Median follow-up for overall survival (OS) was 4.8 years. Complete remissions (CR) were achieved in 92% with ATO/ATRA and 82% with CTX/ATRA; induction death rates were 8% and 18%, respectively. For analysis of postremission outcomes we combined the ATO/ATRA and CTX/ATRA/ATO groups (ATO/ATRA ± CTX). Cumulative incidence of relapse (CIR) was significantly lower after ATO/ATRA ± CTX compared with CTX/ATRA (P < 0.001). The same held true when restricting the analysis according to the treatment period after the year 2000. OS of patients in CR1 was not different between ATO/ATRA ± CTX compared with CTX/ATRA (P = 0.20). High (>10 × 109/l) white blood cell (WBC) counts at diagnosis were associated with higher CIR (P < 0.001) compared with lower WBC in the CTX/ATRA group, but not in the ATO/ATRA ± CTX group (P = 0.48). ATO, when added to ATRA or CTX/ATRA is feasible and effective in elderly patients for remission induction and consolidation, particularly in patients with high WBC at diagnosis.
dc.description.abstract
Open Access funding enabled and organized by Projekt DEAL.
dc.format
application/pdf
dc.publisher
Springer Nature
dc.relation
Leukemia;34(9)
dc.relation
https://doi.org/10.1038/s41375-020-0758-4
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Leucèmia mieloide aguda - Quimioteràpia
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
dc.subject
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
dc.title
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
